Skip to main content
. 2015 Jul 6;10(7):e0131922. doi: 10.1371/journal.pone.0131922

Fig 2. Comparison of immune activation parameters in immunologic or virologic progressor HICs, non-progressor HICs, ART-treated patients, chronic viremic patients and healthy donors.

Fig 2

(A) Proportion of activated circulating HLA-DR+CR38+ CD4+ T cells. (B) Proportion of activated circulating HLA-DR+CD38+ CD8+ T cells. (C) Plasma IP10 levels (pg/mL, logarithmic scale).